(CTNM) Contineum Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 498m USD | Total Return: 119.3% in 12m

Stock Small Molecules, Neuroscience, Inflammation, Immunology
Total Rating 46
Safety 80
Buy Signal -0.51
Biotechnology +0.2
Pharmaceuticals -0.1
Market Cap: 498m
Avg Trading Vol: 4.01M USD
ATR: 8.75%
Peers RS (IBD): 84.2
Risk 5d forecast
Volatility85.7%
Rel. Tail Risk-9.89%
Reward TTM
Sharpe Ratio1.06
Alpha64.56
Character TTM
Beta1.126
Beta Downside0.702
Drawdowns 3y
Max DD84.37%
CAGR/Max DD-0.12
EPS (Earnings per Share) EPS (Earnings per Share) of CTNM over the last years for every Quarter: "2021-12": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": -1.44, "2024-03": -3.55, "2024-06": -0.39, "2024-09": -0.4, "2024-12": -0.56, "2025-03": -0.62, "2025-06": -0.62, "2025-09": -0.45, "2025-12": -0.49, "2026-03": 0,
EPS CAGR: 25.46%
EPS Trend: 67.4%
Last SUE: 0.78
Qual. Beats: 0
Revenue Revenue of CTNM over the last years for every Quarter: 2021-12: null, 2022-12: 0, 2023-03: 0, 2023-06: 50, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.242, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: -30.1%
Last SUE: -1.65
Qual. Beats: 0
Risks
Technicals: volatile
Description: CTNM Contineum Therapeutics

Contineum Therapeutics, Inc. (CTNM) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neurological, inflammatory, and immunological conditions.

Its primary asset, PIPE-791, is an LPA1R inhibitor targeting idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. The company also has PIPE-307, an M1 receptor inhibitor in Phase 2 trials for depression and relapsing-remitting multiple sclerosis, and CTX-343, another LPA1R antagonist.

The biopharmaceutical sector is characterized by lengthy and expensive drug development cycles, with high attrition rates for drug candidates. Many companies in this sector operate with a business model focused on research and development, often relying on venture capital or public offerings to fund clinical trials.

Contineum Therapeutics, Inc. was founded in 2009 and is based in San Diego, California. For deeper analysis of CTNMs financials and market position, consider exploring ValueRay.

Headlines to Watch Out For
  • PIPE-791 clinical trial results impact stock
  • PIPE-307 Phase 2 trial outcomes crucial
  • Regulatory approvals for new therapies drive value
  • Competition in neuroscience and immunology markets
  • Funding for ongoing research and development essential
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.20 > 0.02 and ΔFCF/TA -4.40 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.20 > 3% & CFO -55.3m > Net Income -60.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 27.50 > 1.5 & < 3
Outstanding Shares: last quarter (30.9m) vs 12m ago 19.37% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.11%; Δ -0.11% > 0%)
Interest Coverage Ratio: -15.70 > 6 (EBITDA TTM -63.7m / Interest Expense TTM -4.08m)
Altman Z'' -9.61
A: 0.93 (Total Current Assets 267.9m - Total Current Liabilities 9.74m) / Total Assets 276.6m
B: -0.64 (Retained Earnings -177.4m / Total Assets 276.6m)
C: -0.26 (EBIT TTM -64.1m / Avg Total Assets 244.7m)
D: -11.31 (Book Value of Equity -177.1m / Total Liabilities 15.7m)
Altman-Z'' Score: -9.61 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 0.0/242k)
GMI: 1.00 (fallback, negative margins)
AQI: 65.66 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: none (Revenue 0.0 / 242k)
TATA: -0.02 (NI -60.0m - CFO -55.3m) / TA 276.6m)
Beneish M-Score: cannot calculate (missing components)
What is the price of CTNM shares? As of April 06, 2026, the stock is trading at USD 13.06 with a total of 430,095 shares traded.
Over the past week, the price has changed by +0.75%, over one month by -4.68%, over three months by +34.40% and over the past year by +119.25%.
Is CTNM a buy, sell or hold? Contineum Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CTNM.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CTNM price?
Wallstreet Target Price 22 68.5%
Analysts Target Price 22 68.5%
CTNM Fundamental Data Overview as of 05 April 2026
P/S = 11.147
P/B = 1.7424
Revenue TTM = 0.0 USD
EBIT TTM = -64.1m USD
EBITDA TTM = -63.7m USD
Long Term Debt = 8.25m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.34m USD (from shortTermDebt, last quarter)
Debt = 8.25m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -67.4m USD (from netDebt column, last quarter)
Enterprise Value = 243.4m USD (498.1m + Debt 8.25m - CCE 262.9m)
Interest Coverage Ratio = -15.70 (Ebit TTM -64.1m / Interest Expense TTM -4.08m)
EV/FCF = -4.38x (Enterprise Value 243.4m / FCF TTM -55.5m)
FCF Yield = -22.82% (FCF TTM -55.5m / Enterprise Value 243.4m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 245k) / Revenue TTM)
 Tobins Q-Ratio = 0.88 (Enterprise Value 243.4m / Total Assets 276.6m)
 Interest Expense / Debt = -49.44% (Interest Expense -4.08m / Debt 8.25m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -50.6m (EBIT -64.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.50 (Total Current Assets 267.9m / Total Current Liabilities 9.74m)
Debt / Equity = 0.03 (Debt 8.25m / totalStockholderEquity, last quarter 261.0m)
 Debt / EBITDA = 1.06 (negative EBITDA) (Net Debt -67.4m / EBITDA -63.7m)
 Debt / FCF = 1.21 (negative FCF - burning cash) (Net Debt -67.4m / FCF TTM -55.5m)
 Total Stockholder Equity = 199.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.51% (Net Income -60.0m / Total Assets 276.6m)
RoE = -30.08% (Net Income TTM -60.0m / Total Stockholder Equity 199.4m)
RoCE = -30.85% (EBIT -64.1m / Capital Employed (Equity 199.4m + L.T.Debt 8.25m))
 RoIC = -25.38% (negative operating profit) (NOPAT -50.6m / Invested Capital 199.4m)
 WACC = 9.78% (E(498.1m)/V(506.3m) * Re(9.94%) + (debt cost/tax rate unavailable))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.82%
 [DCF] Fair Price = unknown (Cash Flow -55.5m)
 EPS Correlation: 67.41 | EPS CAGR: 25.46% | SUE: 0.78 | # QB: 0
Revenue Correlation: -30.15 | Revenue CAGR: 0.0% | SUE: -1.65 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.56 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-12-31): EPS=-2.06 | Chg7d=+0.143 | Chg30d=+0.143 | Revisions Net=-3 | Growth EPS=+5.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.17 | Chg7d=-0.082 | Chg30d=-0.082 | Revisions Net=-2 | Growth EPS=-5.8% | Growth Revenue=-68.0%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle